West German Cancer Center, Department for Gynaecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
J Gynecol Oncol. 2021 Jan;32(1):e7. doi: 10.3802/jgo.2021.32.e7. Epub 2020 Oct 14.
Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial cancer (EC). Optimal locoregional control without adjuvant radiotherapy and acceptable surgical morbidity should be achieved concomitantly sparing systematic lymphadenectomy (LNE) for most of the patients.
We evaluated data from 132 patients treated for EC. Out of these, between January 2017 and June 2020 we performed robotic PMMR and TCL on 51 women. We present the first data of feasibility and safety of the procedure as well as preliminary oncological results.
The 51 patients treated with robotic PMMR and TCL showed comparable morbidity to classic laparoscopic hysterectomy or PMMR without LNE. One intraoperative complication occurred. Postoperative complications grade 3 and higher occurred in 2 cases (3.9%). One of these (85 years old) experienced grade 5 following pulmonary embolism with lysis therapy. Fifteen patients (29.4%) could be spared complete LNE. The rate of adjuvant radiotherapy was 3.9% in our collective (n=2), compared to 39.2% of patients (n=20) eligible for irradiation according to international guidelines. In a mean follow-up time of 15 months (0-41), no locoregional recurrences were observed, although three patients showed distant relapse.
Our data suggest that robotic PMMR and pelvic TCL can be performed regardless of BMI and comorbidities without a relevant increase in surgical morbidity. Moreover, despite a relevant reduction of adjuvant radiotherapy, first follow-up data hint at a favorable locoregional recurrence rate in the reported cohort.
腹膜系膜切除术 (PMMR) 加靶向分区淋巴结切除术 (TCL) 旨在切除子宫内膜癌 (EC) 的局部区域癌症病灶。在不接受辅助放疗的情况下实现最佳局部区域控制,同时接受可接受的手术发病率,对于大多数患者应避免进行系统淋巴结切除术 (LNE)。
我们评估了 132 名接受 EC 治疗的患者的数据。在这些患者中,我们在 2017 年 1 月至 2020 年 6 月期间对 51 名女性进行了机器人 PMMR 和 TCL。我们介绍了该手术的可行性和安全性以及初步肿瘤学结果的首批数据。
51 名接受机器人 PMMR 和 TCL 治疗的患者与经典腹腔镜子宫切除术或无 LNE 的 PMMR 的发病率相当。术中发生 1 例并发症。2 例发生术后并发症 3 级及以上(3.9%)。其中 1 例(85 岁)因肺栓塞伴溶栓治疗发生 5 级。15 名患者(29.4%)可避免进行完全 LNE。根据国际指南,我们的患者中接受辅助放疗的比例为 3.9%(n=2),而有放疗适应证的患者比例为 39.2%(n=20)。在平均随访时间为 15 个月(0-41)的情况下,尽管有 3 例患者出现远处复发,但未观察到局部区域复发。
我们的数据表明,无论 BMI 和合并症如何,机器人 PMMR 和盆腔 TCL 均可在不增加手术发病率的情况下进行。此外,尽管辅助放疗的比例显著降低,但报告队列的初步随访数据提示局部区域复发率有利。